Hemostemix Stock Price

TSXV:HEMCA$21.8mPharmaceuticals & Biotech

HEM Share Price Performance

HEM Community Fair Values

View all narratives

Recent HEM News & Updates

No updates

Hemostemix Inc. Competitors

About HEM

Founded: n/a
Employees: n/a
CEO: Thomas Smeenk
WebsiteView website: hemostemix.com

Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopathy, chronic limb threatening ischemia, vascular dementia, and brain function. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.

Hemostemix Inc. Key Details

Last Reported Earnings

Mar 31, 2025

Yearly revenue growth

n/a

Earnings per share (EPS): -0.024
Gross Margin: 0%
Net Profit Margin: 0%
Debt/Equity Ratio: -62.9%

View full report ›

Canadian Market Performance

7 Days: 1.1%
3 Months: 16.0%
1 Year: 18.7%
Year to Date: 8.7%

The market has climbed 1.1% in the last 7 days, lead by the Financials sector with a gain of 1.3%. The market is up 19% over the last 12 months. Looking forward, earnings are forecast to grow by 12% annually. Market details ›